Literature DB >> 23474045

L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?

Gary S Hoffman1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474045     DOI: 10.1016/j.lpm.2013.01.047

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


× No keyword cloud information.
  4 in total

Review 1.  Treatment of primary systemic necrotizing vasculitides: the role of biotherapies.

Authors:  Loïc Guillevin
Journal:  Clin Exp Nephrol       Date:  2013-09-10       Impact factor: 2.801

Review 2.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

Review 3.  Treatment of severe and/or refractory ANCA-associated vasculitis.

Authors:  Loïc Guillevin
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

Review 4.  Central and Peripheral Nervous System Complications of Vasculitis Syndromes From Pathology to Bedside: Part 1-Central Nervous System.

Authors:  Gelsomina Mansueto; Giuseppe Lanza; Francesco Fisicaro; Danielle Alaouieh; Emily Hong; Sara Girolami; Marco Montella; Alessandro Feola; Mario Di Napoli
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-09       Impact factor: 6.030

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.